Browse

Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection

Cited 45 time in Web of Science Cited 56 time in Scopus
Authors
Cheon, Jae Hee; Kim, Nayoung; Lee, Dong Ho; Kim, Jung Mogg; Kim, Joo Sung; Jung, Hyun Chae; Song, In Sung
Issue Date
2006-01-21
Publisher
Wiley-Blackwell
Citation
Helicobacter. 2006 Feb;11(1):46-51.
Keywords
AdultAmoxicillin/therapeutic useAnti-Bacterial Agents/adverse effects/*therapeutic useAza Compounds/*therapeutic useFemaleHelicobacter Infections/*drug therapyHelicobacter pylori/*drug effectsHumansMaleMetronidazole/therapeutic useMiddle AgedOmeprazole/therapeutic useOrganometallic Compounds/therapeutic usePatient ComplianceQuinolines/*therapeutic useTetracycline/therapeutic useTreatment Outcome
Abstract
BACKGROUND AND AIM: Metronidazole and tetracycline-based second-line quadruple therapy, widely used for Helicobacter pylori infection, often ends up in failure due to antibiotic resistance and poor compliance in Korea. Our aim is to evaluate the efficacy and tolerability of moxifloxacin-based triple therapy as an alternative second-line treatment for H. pylori infection. METHODS: The subjects consisted of 85 patients infected with H. pylori, in whom initial proton pump inhibitor triple therapy had failed. They were randomized to receive the following 7-day therapy: 1, moxifloxacin 400 mg q.d., esomeprazole 20 mg b.i.d., and amoxicillin 1 g b.i.d.; and 2, esomeprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. Eradication rates, drug compliance, and side-effect rates of each group were evaluated. RESULTS: The eradication rates were 75.6 and 83.8% with moxifloxacin triple therapy, and 54.5 and 72.7% with quadruple therapy by intention-to-treat (p = .042) and per-protocol analyses (p = .260), respectively. Moxifloxacin triple therapy was significantly superior to quadruple therapy in terms of side-effect rates (p = .039). Compliance for therapy, i.e., the percentage of tablets taken (> 85%), was 90.2 and 75.0%, numerically higher in moxifloxacin triple therapy group than in quadruple therapy group, but without statistical difference (p = .065). CONCLUSIONS: Moxifloxacin-based triple therapy showed high eradication rates with few side effects and good drug compliance, suggesting this regimen could be a safe and effective option as second-line therapy for H. pylori infection in Korea.
ISSN
1083-4389 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16423089

https://hdl.handle.net/10371/21386
DOI
https://doi.org/10.1111/j.0083-8703.2006.00371.x
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse